Please login to the form below

Not currently logged in
Email:
Password:

Caplyta

This page shows the latest Caplyta news and features for those working in and with pharma, biotech and healthcare.

Intra-Cellular soars on FDA approval of schizophrenia drug

Intra-Cellular soars on FDA approval of schizophrenia drug

Intra-Cellular has argued that this differentiates Caplyta from existing schizophrenia drugs, maintaining that it provides additional benefits such as improved psychosocial functioning. ... The approval is an early Christmas present for Intra-Cellular,

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

Parkinson’s disease: past, present and future
Examining the history and complexities of Parkinson’s disease – one of the most prevalent neurodegenerative disorders that affects over 10 million people worldwide...
The 17th World Congress on Controversies in Neurology
This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...